Last Updated: June 22, 2026

SOLIFENACIN Drug Patent Profile

Name: SOLIFENACIN Drug Patent, Exclusivity, and Generic Launch Dataset
Creator: DrugPatentWatch
License: https://www.drugpatentwatch.com/terms.php

✉ Email this page to a colleague

« Back to Dashboard

Which patents cover Solifenacin, and what generic alternatives are available?

Solifenacin is a drug marketed by Accord Hlthcare, Ajanta Pharma Ltd, Alembic, Alkem Labs Ltd, Amneal Pharms Co, Annora Pharma, Aurobindo Pharma, Bostal, Breckenridge, Chartwell Rx, Cipla, Glenmark Speclt, Jubilant Generics, Lannett Co Inc, Macleods Pharms Ltd, MSN, Novitium Pharma, Qilu, Rising, Sciegen Pharms, Sunshine, Teva Pharms Usa, Torrent, Unichem, Watson Labs Inc, and Zydus Pharms. and is included in twenty-six NDAs.

The generic ingredient in SOLIFENACIN is solifenacin succinate. There are thirty drug master file entries for this compound. Twenty suppliers are listed for this compound. Additional details are available on the solifenacin succinate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Solifenacin

A generic version of SOLIFENACIN was approved as solifenacin succinate by TEVA PHARMS USA on April 2^nd, 2014.

Start Trial

AI Deep Research

Questions you can ask:

What is the 5 year forecast for SOLIFENACIN?
What are the global sales for SOLIFENACIN?
What is Average Wholesale Price for SOLIFENACIN?

Summary for SOLIFENACIN

US Patents:	0
Applicants:	26
NDAs:	26
Drug Prices:	Drug price information for SOLIFENACIN
DailyMed Link:	SOLIFENACIN at DailyMed

Drug patent expirations by year for SOLIFENACIN

US Patents and Regulatory Information for SOLIFENACIN

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Sunshine	SOLIFENACIN SUCCINATE	solifenacin succinate	TABLET;ORAL	213346-001	Apr 13, 2020		DISCN	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Msn	SOLIFENACIN SUCCINATE	solifenacin succinate	TABLET;ORAL	210688-002	May 20, 2019	AB	RX	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Watson Labs Inc	SOLIFENACIN SUCCINATE	solifenacin succinate	TABLET;ORAL	202551-001	May 20, 2019	AB	RX	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.